Literature DB >> 6327899

Evaluation of cold-adapted and temperature-sensitive mutants of parainfluenza virus type 3 in weanling hamsters.

F K Crookshanks, R B Belshe.   

Abstract

Cold-adapted (ca) and temperature-sensitive (ts) mutants of parainfluenza virus 3 were produced by serially passaging wild type (wt) parainfluenza virus 3 at 20 degrees C 45 times. Previously, plaque-purified viruses (clones) were selected from the wt parent and from cold passage levels 7, 12, 18, and 45 and characterized in vitro. In the present study, we evaluated at least one mutant from each cold passage level for attenuation in hamsters. Four of the five mutants tested were ts and ca (one each from cold passage levels 7, 12, 18, and 45) and one was ca but not ts (from cold passage 18). Groups of hamsters were inoculated intranasally with either parent wt or mutant virus. Four or five hamsters from each group were sacrificed prior to inoculation and daily on the first, second, third, fourth, and sixth or seventh day postinoculation and the amount of virus in nasal turbinates and lungs was quantitated. The quantity of virus recovered from the hamsters and the parainfluenza virus 3 antibody titers were inversely related to the cold passage level. Two of the mutants did not replicate in hamsters. Cold adaptation of parainfluenza virus 3 resulted in progressive attenuation of the virus in weanling hamsters. These highly attenuated mutants are suitable for evaluation in children as live virus vaccines.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6327899     DOI: 10.1002/jmv.1890130306

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees.

Authors:  M L Clements; R B Belshe; J King; F Newman; T U Westblom; E L Tierney; W T London; B R Murphy
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

2.  Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.

Authors:  M H Skiadopoulos; A P Durbin; J M Tatem; S L Wu; M Paschalis; T Tao; P L Collins; B R Murphy
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 3.  Current approaches to the development of vaccines effective against parainfluenza viruses.

Authors:  B R Murphy
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

4.  Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.

Authors:  T Tao; M H Skiadopoulos; F Davoodi; J M Riggs; P L Collins; B R Murphy
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  Pathogenesis of human parainfluenza virus 3 infection in two species of cotton rats: Sigmodon hispidus develops bronchiolitis, while Sigmodon fulviventer develops interstitial pneumonia.

Authors:  D D Porter; G A Prince; V G Hemming; H G Porter
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

6.  Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.

Authors:  M H Skiadopoulos; S Surman; J M Tatem; M Paschalis; S L Wu; S A Udem; A P Durbin; P L Collins; B R Murphy
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

7.  Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.

Authors:  Janet A Englund; Ruth A Karron; Coleen K Cunningham; Philip Larussa; Ann Melvin; Ram Yogev; Ed Handelsman; George K Siberry; Bhavanji Thumar; Elizabeth Schappell; Catherine V Bull; Helen Y Chu; Anne Schaap-Nutt; Ursula Buchholz; Peter L Collins; Alexander C Schmidt
Journal:  Vaccine       Date:  2013-10-05       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.